The per capita number of outpatient visits in which an antipsychotic drug was supplied or prescribed increased approximately 660% among children and 380% among adolescents between the mid-1990s and the mid-2000s in the United States, 1 prompting concerns about possible inappropriate prescribing. The most recent revisions to the DSM-5 were intended in part to decrease inappropriate child and adolescent antipsychotic drug use, 2 and the American Psychiatric Association has warned against using antipsychotics as first-line therapy in children and adolescents for conditions other than psychotic disorders. 3 To quantify acute harms from child and adolescent antipsychotic drug use, we estimated the numbers and rates of US emergency department (ED) visits and hospitalizations for adverse drug events (ADEs) from therapeutic use of antipsychotics and comparator psychotropic medications among children 10 years or younger and adolescents 11 to 18 years.
Methods | We used the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance (NEISS-CADES) system to estimate child and adolescent US ADE ED visits from antipsychotics, antidepressants, and stimulants available only by prescription (2009-2011) and estimated child and adolescent outpatient prescription visits using the National Ambulatory Medical Care and National Hospital Ambulatory Medical Care Surveys (2009-2010). [4] [5] [6] We excluded ADE ED visits resulting from therapeutic failures, nonadherence, drug withdrawal, and nontherapeutically intentioned use (intentional self-harm, drug abuse, or unsupervised ingestions) or involving ADEs that led to a patient's death in or before arrival at the ED. We also calculated the annual number of ADE ED visits per 10 000 outpatient visits at which each medication was prescribed. We classified medications as antipsychotics, antidepressants, or stimulants; categorized adverse effects; and calculated 95% CIs as described by Hampton et al. 4 The human participant oversight bodies of the Centers for Disease Control and Prevention and Food and Drug Administration determined the methods and analyses in this study to be public health surveillance activities and did not require institutional review board approval or patient consent.
Results | From 2009 through 2011, there were an estimated 1350 antipsychotic ADE ED visits (95% CI, 821-1879) involving children 10 years and younger and 2674 visits (95% CI, 1779-3569) involving adolescents 11 to 18 years old annually in the United States ( Table 1) . Patients were admitted, held for observation, or transferred to another acute care facility after 18.6% of child and adolescent antipsychotic ADE ED visits (95% CI, 12.3%-24.9%), a hospitalization rate higher than the 7.3% rate (95% CI, 4.0%-10.5%) for nonantipsychotic ADE ED visits. Atypical antipsychotics were implicated in 97.6% of child antipsychotic ADE ED visits (95% CI, 94.0%-100.0%) and 83.4% of adolescent visits (95% CI, 77.2%-89.7%). Among children, antipsychotics were implicated in ADE ED visits at a 3.9-fold higher rate than stimulants (17.6 vs 4.5 ADE ED visits per 10 000 outpatient prescription visits) ( Table 2) . Among adolescents, antipsychotics were implicated in ADE ED visits at a 3.8-fold higher rate than stimulants (14.6 vs 3.8 ADE ED visits per 10 000 outpatient prescription visits) and a 2.7-fold higher rate than antidepressants (14.6 vs 5.5 ADE ED visits per 10 000 outpatient prescription visits). Movement disorders, including dystonia, extrapyramidal disorders, and muscle spasticity, were the most common antipsychotic drug adverse effects, occurring in 47.7% of child and adolescent antipsychotic ADE ED visits (95% CI, 37.8%-57.6%).
Discussion | Adverse events from therapeutically intentioned use of antipsychotics cause thousands of child and adoles-cent ED visits annually in the United States and significantly more ED visits relative to their outpatient use than either stimulants or antidepressants. These national estimates are probably conservative because the NEISS-CADES may be biased toward the detection of drug adverse effects that are acute, known, testable in an ED, or readily distinguished from problems caused by patients' comorbidities. 4 Chronic problems from medication use, such as metabolic disorders associated with antipsychotics, 3 are unlikely to be identified by the NEISS-CADES. In addition, the NEISS-CADES does not collect information on the specific indication for each medication implicated in an ADE or on whether a medication was used on label or off label. National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey data are commonly used to estimate outpatient medication use 1, 4 ; however, they do not provide direct estimates of person-year exposure to medications and may overestimate or underestimate the use of psychiatric medications. The higher rates of antipsychotic ADE ED visits should remind clinicians of antipsychotics' risks and of the importance of heeding the American Psychiatric Association's warning that antipsychotics should be used cautiously. 3 Nationally representative public health surveillance data may be useful in assessing the impact of efforts to reduce inappropriate antipsychotic drug use on ADEs. 
Suicide in a Health Maintenance Organization Population
The US Surgeon General and the Institute of Medicine have called for health care systems to help reduce the number of suicides. 1,2 However, the few assessments of suicide in such systems have examined specific patient groups rather than the entire population of health plan members. 3, 4 Here we report, to our knowledge, the first information on suicide for the entire membership of a large health maintenance organization (HMO) network.
Methods | We identified all suicides among the membership of our HMO network between 1999 and 2010, determining the date and cause of death using official state mortality records. We linked these data to the medical record by name, sex, address, date of birth, and social security number. Using the Centers for Disease Control and Prevention's external cause of injury mortality matrix, we designated as suicides all deaths with International Statistical Classification of Diseases, Tenth Revision codes X60-X84 or Y87.0. The Centers for Disease Control and Prevention first used this scheme to classify deaths in 1999, the first year of our study period.
We characterized suicides among 5 study groups: all individuals enrolled in our HMO network (members); all members who did (patients) or did not (nonpatient members) access health care network services during that membership year; and patients who did (mental health [MH] patients) or did not (non-MH patients) make at least 1 visit to the network's specialty MH services department that year. We defined suicide rates in accordance with the State of Michigan's vital statistics (ie, per 100 000 population), effectively keeping risk time constant based on the nature of the HMO membership. We used standard linear regression, with annual suicide rate as the dependent variable, to evaluate rates over time with statistical significance defined as P < .05.
The institutional review boards at Henry Ford Hospital and the State of Michigan approved this project; patient consent was waived.
Results | During the 11-year study, the annual HMO network membership ranged from 182 183 to 293 228 and was demographically representative of southeast Michigan, with approximately 25% older than the age of 65 years, 55% female, and 40% white. On average each year, approximately 65% of members were patients, and approximately 60% of patients were MH patients. There were 160 suicides among all HMO members ( Table 1) .
The mean annual suic ide rate for members was 5.77 per 100 000 and did not significantly change over the study period (P = .20) ( Table 2) , whereas the annual suicide rate in the general population of the state of Michigan inc reased signific antly (P < .001) (mean, 10.82 per 100 000).
The mean annual suicide rate among patients (6.38 per 100 000) and nonpatient members (4.47 per 100 000) was similar to that for all members (5.77 per 100 000), and likewise did not change ( Table 2) . Suicide rates declined for MH patients (P < .04) but increased for non-MH patients (P < .01).
Discussion | This report presents the first description of suicide rates in the entire membership of a large HMO. To our knowledge, the only other available studies examining suicide in insured populations within the United States are limited to 2 specific patient populations: military veterans 4 and patients receiving treatment for depression. 3 In our sample, the first to include nonpatient members, the annual suicide
